Inhaled frusemide and exercise-induced bronchoconstriction in children with asthma

Paul Munyard, K Fan Chung, Andrew Bush

Abstract

Background – Nebulised frusemide has been shown to be protective against bronchoconstricting stimuli in adult asthmatic subjects and against cold air challenge in children. Animal studies suggest that inhaled frusemide may be more effective in the young.

Methods – A double blind placebo, controlled, crossover study on the effect on exercise of pretreatment with frusemide (20 mg) from a metered dose inhaler via a large volume spacer (Volumatic) was performed in 12 asthmatic children. Exercise testing consisted of eight minutes of running on a treadmill in an environmentally controlled laboratory.

Results – Deterioration in lung function was less after frusemide than after the placebo exercise tests. The mean (95% CI) maximum percentage falls in forced expiratory volume in one second (FEV₁) were 14.4% (7.7 to 21.0) for placebo and 5.7% (2.3 to 9.0) for frusemide.

Conclusions – Inhaled frusemide via a metered dose inhaler reduces exercise-induced bronchoconstriction in children.

(Thorax 1995;50:677-679)

Keywords: asthma, children, frusemide.

Nebulised (but not intravenous or oral) frusemide has been shown in adult asthmatic subjects to be protective against bronchoconstriction induced by allergen,¹ exercise,² ultrasonically nebulised water,³ and nebulised sodium metabisulphite.⁴ Nebulised frusemide also protects against cold air-induced bronchoconstriction in children with mild to moderate asthma.⁵

Animal studies suggest a more pronounced effect and a longer duration of action of frusemide in newborn than in adult guinea pigs⁶; there is therefore a need for studies in children to establish its protective profile.

Methods

SUBJECTS

Twelve patients (eight boys) aged 7-14 years (mean 10.6 years) were recruited from the asthma clinic of the Royal Brompton Hospital. Patients were recruited if they complained of exercise-induced asthma and agreed to participate in the study. Asthma was diagnosed on the basis of both a clinical history of intermittent respiratory symptoms and either a

peak flow lability of 20% or an improvement in forced expiratory flow in one second (FEV₁) of 15% with inhaled β_2 agonists. All patients were on inhaled prophylactic therapy (11 budesonide, dosage range 200-1600 μ g per day; one disodium cromoglycate). No patient was taking oral steroids, theophyllines, long acting β_2 agonists, or antihistamines at the time of the study. All patients were free from respiratory infection for at least one month before the study. Written informed consent was obtained from their parents, verbal consent from the child, and the protocol was approved by the hospital ethics committee.

PROTOCOL

We conducted a double blind placebo controlled crossover trial with standardised exercise testing. Before testing disodium cromoglycate was withheld for 24 hours, inhaled β_2 agonists for six hours, and inhaled steroid therapy was unchanged. Three standardised exercise tests were undertaken at the same time of day, all within a period of seven days as previously recommended.⁷ Frusemide (20 mg) or matched placebo (Hoechst UK Ltd) was administered by metered dose inhaler (5 mg/puff) through a Volumatic 750 ml spacer (Allen & Hanburys) in random order.

Flow-volume loops were performed with a portable compact spirometer (Vitalograph UK), selecting the loop with the best FEV₁ from three technically satisfactory measurements. Spirometric tests were performed at baseline (before frusemide or placebo administration), at four minutes during the exercise, at the end of exercise, and at 2, 4, 6, 8, 10, 15, 20, and 30 minutes after exercise.

EXERCISE TESTING

The exercise testing consisted of eight minutes of running on a treadmill with increasing speed and gradient to a maximum of 4.5 miles per hour and 15% incline. Subjects were exercised up to 85% of their age predicted maximal heart rate. Tests were performed in an air conditioned laboratory under controlled and identical environmental conditions.

STATISTICAL ANALYSIS

The results were normalised by dividing by the baseline measurement on that particular day. The results from the three exercise tests were analysed by two way analysis of variance using the statistics package SPSS.

Department of
Paediatrics
P Munyard
A Bush

Department of
Thoracic Medicine
K F Chung

National Heart and
Lung Institute,
London SW3 6LY, UK

Reprint requests to:
Dr A Bush.

Received 21 July 1994
Returned to authors
28 September 1994
Revised version received
13 December 1994
Accepted for publication
28 February 1995

Baseline FEV₁ (actual value (l/min), percentage predicted, and means) on control, placebo, and frusemide days

Patient	Control	Placebo	Frusemide
1	1.91 (72%)	1.87 (70%)	1.86 (70%)
2	1.98 (90%)	1.93 (88%)	1.88 (85%)
3	1.93 (72%)	1.93 (72%)	1.83 (69%)
4	3.22 (94%)	3.15 (92%)	3.23 (95%)
5	1.71 (98%)	1.73 (99%)	1.73 (99%)
6	2.42 (98%)	2.37 (96%)	2.52 (102%)
7	1.35 (96%)	1.38 (99%)	1.34 (96%)
8	1.62 (87%)	1.62 (87%)	1.58 (84%)
9	1.34 (82%)	1.34 (82%)	1.32 (81%)
10	1.41 (89%)	1.25 (78%)	1.27 (79%)
11	2.48 (83%)	2.64 (88%)	2.72 (90%)
12	2.57 (82%)	2.48 (80%)	2.39 (77%)
Mean	2.0 (86.9%)	2.0 (85.9%)	2.0 (85.6%)

Figure 1 Maximal percentage fall from baseline in FEV₁ (actual values, means, and standard error of means (error bars)).

Results

There were no significant differences in baseline FEV₁, peak expiratory flow rate (PEFR), or forced mid expiratory volume (FEF₂₅₋₇₅) between the three study days. The mean (SE) percentage predicted values for baseline FEV₁ were: control 86.9% (2.6%), placebo 85.9% (2.8%), and frusemide 85.6% (3.2%). The

Figure 2 Percentage change from baseline in FEV₁ over the time of the study for the three exercise tests.

FEV₁ values (actual values, percentage predicted, and means) are shown in the table.

The mean maximal (SE) percentage falls in FEV₁ are shown in fig 1. The mean (95% confidence intervals) maximal percentage falls in FEV₁ were: control 15.4% (7.5 to 23.3), placebo 14.4% (7.7 to 21.0), frusemide 5.7% (2.3 to 9.0). The results for the control and placebo days were not statistically different, while the results for the frusemide day were statistically different from both the control and placebo days (p=0.005). Thus, the degree of protection afforded by frusemide (calculated as the differences in changes of lung function after placebo and frusemide expressed as percentage of the change after placebo) was 60%.

The mean (95% confidence intervals) maximal percentage falls in PEF_R were: control 18.4% (13.2 to 23.6), placebo 21.1% (12.0 to 30.2), frusemide 12.5% (7.7 to 17.2). The differences with frusemide treatment did not reach statistical significance. There was no statistically significant difference between mean maximal percentage falls in FEF₂₅₋₇₅.

Figure 2 shows the percentage change from baseline in FEV₁ over the time of the study for the three exercise tests.

Discussion

We have shown that frusemide, delivered by a metered dose inhaler and spacer, is protective against exercise-induced bronchoconstriction in asthmatic children on prophylactic therapy. This is the first use of frusemide by this route in children. A previous study in children⁵ found a similar degree of protection in FEV₁ (63%) as our study, but the patient characteristics, stimulus, dose, and route of drug administration were different. We did not study mildly asthmatic children, and further studies are needed to compare β_2 agonists and frusemide in this situation. The placebo effect gave minor, statistically insignificant protection in FEV₁ and FEF₂₅₋₇₅. The degree of protection afforded to FEV₁ in adult studies has been reported at 67% and 62%.²⁸ The results from our study were similar, with no greater efficacy of frusemide in children; however, there were important differences between these studies, including patient characteristics.

We encountered no adverse effects with frusemide administration. The exact mechanism of action of frusemide is yet to be determined. Further studies addressing the duration of this protective effect, its long term safety, and more directly comparable studies in adults and children need to be undertaken.

The authors would like to thank Hoechst for providing the metered dose inhalers and for financial support.

1 Bianco S, Pieroni M, Refini RM, Rottoli L, Sestini P. Protective effect of inhaled furosemide on allergen induced early and late asthmatic reactions. *N Engl J Med* 1989;351: 1069-73.
2 Bianco S, Vaghi A, Roubushi M, Pasargiklian M. Prevention of exercise induced bronchoconstriction by inhaled furosemide. *Lancet* 1988;ii:252-5.
3 Robuschi M, Gambaro G, Spagnotto S, Vaghi A, Bianco S. Inhaled furosemide is highly effective in preventing ultrasonically nebulised water bronchoconstriction. *Pulm Pharmacol* 1987;1:187-91.
4 Nichol GM, Alton EW, Nix A, Geddes DM, Chung KF,

- Barnes PJ. Effect of inhaled furosemide on metabisulfite and methacholine induced bronchoconstriction and nasal potential difference in asthmatic subjects. *Am Rev Respir Dis* 1990;142:576–80.
- 5 Seidenberg J, Dehning J, von der Hart H. Inhaled frusemide against cold air induced bronchoconstriction in asthmatic children. *Arch Dis Child* 1992;67:214–7.
- 6 Stevens EL, Vychara CFT, Southgate WM, Nakamura KT. Furosemide differently relaxes airway and vascular smooth muscle in fetal, newborn and adult guinea-pigs. *Am Rev Respir Dis* 1992;146:1192–7.
- 7 Silverman M, Anderson SD. Standardization of exercise tests in asthmatic children. *Arch Dis Child* 1972;47:882–9.
- 8 Pavord ID, Wisniewski A, Tattersfield AE. Inhaled frusemide and exercise induced asthma: evidence for a role of inhibitory prostanoids. *Thorax* 1992;47:797–800.

Thorax 1995;50:679–681

Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers

S M Kirby, J Smith, G P Ventresca

Abstract

Background – Metered dose inhalers for the treatment of asthma use chlorofluorocarbons as propellants. These face an international ban due to their effect on the ozone layer. Salmeterol has been reformulated using the non-chlorinated propellant Glaxo inhalation grade HFA134a.

Methods – The safety, tolerability and systemic pharmacodynamic activity of the salmeterol/HFA134a inhaler, the current salmeterol inhaler, and placebo (HFA134a) were compared in 12 healthy volunteers in a double blind, randomised crossover study using a cumulative dosing design.

Results – Safety and tolerability were similar and the response was related to the dose over the range used (50–400 µg) with both salmeterol inhalers. The salmeterol/HFA134a inhaler showed no differences from the current inhaler for pulse rate, blood pressure, tremor, QT_c interval, and plasma glucose levels. The salmeterol/HFA134a inhaler had significantly less effect on plasma potassium levels.

Conclusions – In healthy volunteers the salmeterol/HFA134a inhaler is at least as safe and well tolerated as the current salmeterol inhaler, and has similar systemic pharmacodynamic activity.

(*Thorax* 1995;50:679–681)

Keywords: HFA134a, salmeterol, metered dose inhalers.

fluorocarbons as propellants which face an international ban on production from 1995–6 due to their depleting effect on the ozone layer. Because of their “essential use” status, temporary exemptions have been granted for the use of chlorofluorocarbons in metered dose inhalers while satisfactory alternatives are developed. Salmeterol has been reformulated in Glaxo inhalation grade HFA134a (tetrafluoroethane).

Studies in animals have shown HFA134a to be a non-toxic, inert compound. It was well tolerated when given alone to healthy subjects in single and repeat doses up to a maximum of 10 actuations four times daily for 14 days.² HFA134a is rapidly absorbed following inhalation, and rapidly eliminated from the body by ventilation, with no evidence of accumulation or significant metabolism.³

We have investigated the safety and tolerability of the salmeterol/HFA134a inhaler in healthy subjects and compared its systemic pharmacodynamic activity with that of the current salmeterol inhaler using chlorofluorocarbon propellant 11 and 12 (P11/P12).

Methods

Twelve healthy men of mean age 26.9 years (range 19–40) and mean weight 76.1 kg (range 59–92) gave their written informed consent. The study was approved by the local ethics committee and carried out in accordance with the provisions of the Declaration of Helsinki and later revisions.

Subjects received the salmeterol/HFA134a inhaler, the salmeterol/P11/12 inhaler, and placebo (HFA134a) in a double blind, randomised, three-way crossover manner on three different days at least one week apart. Salmeterol doses were cumulative: 50, 50, 100,

Clinical
Pharmacology
Division
S M Kirby
G P Ventresca

Department of
Medical Statistics
J Smith

Glaxo Research and
Development Ltd,
Greenford,
Middlesex UB6 0HE,
UK

Reprint requests to:
Dr G P Ventresca.

Received 9 September 1994
Returned to authors
9 November 1994
Revised version received
10 January 1995
Accepted for publication
6 February 1995

Salmeterol xinafoate is a potent, selective and long acting β_2 adrenoreceptor agonist used in the regular treatment of reversible airways obstruction¹ and available as a metered dose inhaler. Metered dose inhalers use chloro-